WallStreetZenWallStreetZen

NASDAQ: NRXP
Nrx Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NRXP

Based on 5 analysts offering 12 month price targets for Nrx Pharmaceuticals Inc

Min Forecast
$18.00+516.44%
Avg Forecast
$31.40+975.34%
Max Forecast
$46.00+1,475.34%

Should I buy or sell NRXP stock?

Based on 5 analysts offering ratings for Nrx Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NRXP's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NRXP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NRXP stock forecasts and price targets.

NRXP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-08
lockedlocked$00.00+00.00%2025-09-08
lockedlocked$00.00+00.00%2025-04-29
lockedlocked$00.00+00.00%2025-04-02
lockedlocked$00.00+00.00%2025-03-20

1 of 1

Forecast return on equity

Is NRXP forecast to generate an efficient return?

Company
-276.64%
Industry
130.14%
Market
-52.51%
NRXP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NRXP forecast to generate an efficient return on assets?

Company
2,036.49%
Industry
47.48%
NRXP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NRXP earnings per share forecast

What is NRXP's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.57
Avg 2 year Forecast
$0.42
Avg 3 year Forecast
$2.53

NRXP revenue forecast

What is NRXP's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$21.8M
Avg 2 year Forecast
$132.4M
Avg 3 year Forecast
$512.1M

NRXP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NRXP$2.92$31.40+975.34%Strong Buy
CELU$2.15$6.00+179.07%Buy
GANX$1.58$7.25+358.86%Strong Buy
ALGS$9.22$60.00+550.76%Buy
GNTA$3.10N/AN/A
View Top Biotech Stocks

Nrx Pharmaceuticals Stock Forecast FAQ

Is Nrx Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: NRXP) stock is to Strong Buy NRXP stock.

Out of 5 analysts, 2 (40%) are recommending NRXP as a Strong Buy, 3 (60%) are recommending NRXP as a Buy, 0 (0%) are recommending NRXP as a Hold, 0 (0%) are recommending NRXP as a Sell, and 0 (0%) are recommending NRXP as a Strong Sell.

If you're new to stock investing, here's how to buy Nrx Pharmaceuticals stock.

What is NRXP's earnings growth forecast for 2025-2027?

(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.2%.

Nrx Pharmaceuticals's earnings in 2025 is -$33,794,000.On average, 1 Wall Street analyst forecast NRXP's earnings for 2025 to be -$11,231,894, with the lowest NRXP earnings forecast at -$11,231,894, and the highest NRXP earnings forecast at -$11,231,894. On average, 1 Wall Street analyst forecast NRXP's earnings for 2026 to be $8,276,132, with the lowest NRXP earnings forecast at $8,276,132, and the highest NRXP earnings forecast at $8,276,132.

In 2027, NRXP is forecast to generate $49,853,845 in earnings, with the lowest earnings forecast at $49,853,845 and the highest earnings forecast at $49,853,845.

What is NRXP's revenue growth forecast for 2025-2027?

(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Nrx Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NRXP's revenue for 2025 to be $429,570,679, with the lowest NRXP revenue forecast at $429,570,679, and the highest NRXP revenue forecast at $429,570,679. On average, 1 Wall Street analysts forecast NRXP's revenue for 2026 to be $2,608,952,195, with the lowest NRXP revenue forecast at $2,608,952,195, and the highest NRXP revenue forecast at $2,608,952,195.

In 2027, NRXP is forecast to generate $10,090,969,932 in revenue, with the lowest revenue forecast at $10,090,969,932 and the highest revenue forecast at $10,090,969,932.

What is NRXP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NRXP) forecast ROA is 2,036.49%, which is higher than the forecast US Biotechnology industry average of 47.48%.

What is NRXP's Price Target?

According to 5 Wall Street analysts that have issued a 1 year NRXP price target, the average NRXP price target is $31.40, with the highest NRXP stock price forecast at $46.00 and the lowest NRXP stock price forecast at $18.00.

On average, Wall Street analysts predict that Nrx Pharmaceuticals's share price could reach $31.40 by Sep 8, 2026. The average Nrx Pharmaceuticals stock price prediction forecasts a potential upside of 975.34% from the current NRXP share price of $2.92.

What is NRXP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NRXP) Nrx Pharmaceuticals's current Earnings Per Share (EPS) is -$2.24. On average, analysts forecast that NRXP's EPS will be -$0.57 for 2025, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.57. On average, analysts forecast that NRXP's EPS will be $0.42 for 2026, with the lowest EPS forecast at $0.42, and the highest EPS forecast at $0.42. In 2027, NRXP's EPS is forecast to hit $2.53 (min: $2.53, max: $2.53).

What is NRXP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NRXP) forecast ROE is -276.64%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.